Literature DB >> 26356090

Re: Sodium Valproate-Induced Myopathy in a Child.

Josef Finsterer1, Marlies Frank2.   

Abstract

Entities:  

Year:  2015        PMID： 26356090      PMCID： PMC4554286          DOI： 10.18295/squmj.2015.15.03.025

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN： 2075-051X


× No keyword cloud information.
  11 in total

Review 1.  Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders.

Authors:  Josef Finsterer; Sinda Zarrouk Mahjoub
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-12-07       Impact factor: 4.481

2.  Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers.

Authors:  Jana Hroudova; Zdenek Fisar
Journal:  Neuro Endocrinol Lett       Date:  2010       Impact factor: 0.765

3.  [Evolution until death of two members of a family with A3243G mutation and MELAS phenotype versus diabetes mellitus].

Authors:  M I Pérez López-Fraile; R Barrena; J Montoya; E Marta
Journal:  Neurologia       Date:  2006 Jul-Aug       Impact factor: 3.109

4.  Valproate-induced hyperammonemic encephalopathy followed by benzodiazepine withdrawal in a patient with schizoaffective disorder: a differential diagnosis.

Authors:  J Sarlon; E Hess; A Krasnianski
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2013       Impact factor: 2.198

5.  Sodium valproate -- induced skeletal myopathy.

Authors:  L Kasturi; Sangeeta P Sawant
Journal:  Indian J Pediatr       Date:  2005-03       Impact factor: 1.967

6.  Sodium valproate-induced myopathy in a child.

Authors:  Riaz Ahmed
Journal:  Sultan Qaboos Univ Med J       Date:  2015-01-21

7.  Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency.

Authors:  M Kottlors; M Jaksch; U P Ketelsen; S Weiner; F X Glocker; C H Lücking
Journal:  Neuromuscul Disord       Date:  2001-11       Impact factor: 4.296

8.  Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation.

Authors:  Paula B M Luís; Jos P N Ruiter; Cátia C P Aires; Graça Soveral; Isabel Tavares de Almeida; Marinus Duran; Ronald J A Wanders; Margarida F B Silva
Journal:  Biochim Biophys Acta       Date:  2007-07-10

9.  Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed post mortem by identification of p.W748S mutation in POLG gene.

Authors:  Ewa Pronicka; Anna Weglewska-Jurkiewicz; Maciej Pronicki; Jolanta Sykut-Cegielska; Pawel Kowalski; Magdalena Pajdowska; Irena Jankowska; Katarzyna Kotulska; Piotr Kalicinski; Joanna Jakobkiewicz-Banecka; Grzegorz Wegrzyn
Journal:  Med Sci Monit       Date:  2011-04

10.  Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes unveiled by valproate.

Authors:  Neera Chaudhry; Yogesh Patidar; Vinod Puri
Journal:  J Pediatr Neurosci       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.